Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant-Reference-Cited by-同舟云学术

Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant

Published:2017-07-20 Issue:4 Volume:99 Page:300-305
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Randall Kate¹,Kaparou Maria²,Xenou Evgenia²,Paneesha Shankara²,Kishore Bhuvan²,Kanellopoulos Alexandros²,Lovell Richard²,Holder Kathy²,Suhr Julie²,Baker Lynda²,Ryan Lynn²,Nikolousis Emmanouil²^ORCID

Affiliation:

1. Haematology Department; Warwick District general hospital; Warwick UK

2. Haematology Department; Heart of England NHS Trust; Birmingham UK

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12917/fullpdf

Reference36 articles.

1. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia;Tauro;J Clin Oncol,2005

2. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future;Bjorkstrand;Semin Hematol,2007

3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

4. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

5. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy;Tricot;Bone Marrow Transplant,1995

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling;Frontiers in Oncology;2023-10-02

3. Current approaches to management of newly diagnosed multiple myeloma;American Journal of Hematology;2022-03-10